GlassScriptPhysician profile
Amber Breanne Watson
NPI 1043984917
$2,078.20
in general payments reported to CMS, 2019-2025
18 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $143 · 2023: $343 · 2024: $545 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.40 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $593.49 | 2022-2025 | Sublocade, Perseris |
| Alkermes, INC. | $323.78 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $213.83 | 2024-2025 | |
| Braeburn INC. | $158.28 | 2023-2025 | Brixadi |
| Neurocrine Biosciences, INC. | $154.21 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133.16 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $112.47 | 2025 | Sunosi, Auvelity |
| Orexo US, INC. | $67.97 | 2024-2025 | Zubsolv |
| Otsuka America Pharmaceutical, INC. | $60.01 | 2025 | Rexulti |
| Neuronetics, INC. | $59.16 | 2024 | Neurostar Tms Therapy System |
| Teva Pharmaceuticals USA, INC. | $53.45 | 2025 | Uzedy |
| Jazz Pharmaceuticals INC. | $28.88 | 2025 | |
| Boston Scientific Corporation | $28.85 | 2024 | Spyglass Discover |
| Takeda Pharmaceuticals U.S.A., INC. | $22.26 | 2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $20.38 | 2025 | Cobenfy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $17.68 | 2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $15.76 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $14.58 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.